This phase I trial is trying to understand if a new oral drug works and is safe for the treatment of advanced KRAS G12C mutated solid cancers that have spread to other parts of the body.
This trial is treating multiple types of cancer including non-small cell lung cancer, colorectal cancer and other cancers with a KRAS G12C mutation.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase I Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This is a Dose-escalation (Stage I) and Dose expansion (Stage II) trial. Participants eligible for Stage I will receive oral GDC-6036 once daily (PO QD). The dose will be increased in successive cohorts until a safety threshold is observed. Participants with select solid tumours will eligible for Stage II and treated with oral GDC-6036 once daily at a recommended dose.
Recruiting Hospitals Read More